Two drug companies are set to receive funding to produce HIV prevention drug lenacapavir more cheaply, in what one key researcher has called a “huge” step towards getting the jab – seen as a crucial tool for ending the HIV/AIDs pandemic – to lower-income countries.
Lenacapavir will cost $40 (£30) a year for one patient in 120 low- and middle-income countries from 2027 under the deals.
